EUROTIMES - PDF Document

Presentation Transcript

  1. EUROTIMES 2 Editorial ESCRS ™ EDItORIal Volume 18 | Issue 7/8 Medical Editors Ioannis Pallikaris José Güell SCHLEMM’S CANAL SURGERY It is hoped that the new interest in Schlemm’s canal surgery, now rekindled, will continue to grow Clive Peckar Paul Rosen by Clive Peckar International Editorial Board E with a nylon suture (Redmond smith, 1960) or by trabeculectomy (Cairns, 1968) failed; as the openings so created healed. Trabeculectomy carried out with a loosely sutured flap, however, became adopted as a “bleb-dependent sub-conjunctival fistularising procedure”, replacing holth’s procedure (1909) and scheie’s procedure (1958). interest in schlemm’s canal surgery then became dormant, until Robert stegmann, in1991, working with African patients, in whom trabeculectomy had a very low success rate, successfully developed his technique of visco-canalostomy1. in this procedure he approached schlemm’s canal ab-externo and dilated it, in part, with high viscosity sodium hyaluronate, while by-passing the trabecular meshwork, using a “trabeculo-descemetic window”, ± micropunctures, and an intra-scleral reservoir/“lake”. in 2004 he improved his technique further, introducing “canaloplasty”, in which he dilated 360° of schlemm’s canal, using a 250µ microcatheter, developed from arterial catheterisation technology, prior to holding it open, with a 10/0 polypropylene suture. This technique was further refined, in 2008, with the introduction of 9mm polyimide “canal expanders”. Canaloplasty thus became the first physiological surgical procedure, for open-angle, angle recession and congenital glaucoma, which bypassed the trabecular meshwork, and angle, and prevented canal collapse, by dilating and holding open schlemm’s canal and its ostia, together with those of the collector channels, allowing aqueous to drain directly into the aqueous veins. Whilst these procedures have been increasingly adopted by glaucoma surgeons in many parts of Europe, and the Us, they have not been taken up universally due to the relative technical difficulties of the procedures and the perception that they are “not cost-effective”. interestingly in Germany, where canaloplasty is available through the public healthcare system, it has been demonstrated to be more cost effective than trabeculectomy2, when the number of interventions and hospital/clinic visits are taken into account, and to have a better Quality of Life, and greater patient satisfaction, than trabeculectomy3. Another objection to the use of intracanalicular stents has been that they will be occluded by fibrosis, as suggested by Peng Khaw in the Cover story (see page 4). This comparison with other “tube” procedures does not take into account the fibrinolytic activators present in the endothelial cells of schlemm’s canal, its collector channels and aqueous veins, all of which have higher levels of tissue plasminogen activator (t-PA) and lower levels of t-PA inhibitor, compared with vascular endothelium4. it is these activators combined with the fibrinolytic action of sodium hyaluronate that is, in part, responsible for the surgical success of visco-canalostomy1 and canaloplasty5,6. arly attempts to open schlemm’s canal and allow direct drainage of aqueous, via the collector channel drainage system, using an ab-interno approach, goniotomy/ trabeculotomy (Otto Barkan, 1956), or by opening the canal ab-externo and “cheese-wiring” the inner wall of schlemm’s canal in the Cover story of this issue (see page 4) we examine the views of a number of glaucoma surgeons on the development of MiGs (Minimally invasive Glaucoma surgery) and highlight some of the recent devices which allow aqueous direct access into schlemm’s canal. Canal surgery performed with the MiGs ab-interno approach, under gonioscopic vision, has many theoretical advantages and avoids the difficult ab-externo dissection and suturing. however, although the early results using these devices have been encouraging, it should be noted that many of these early studies were combined with phacoemulsification, which alone significantly reduces intraocular pressure (see article page 8), and longer term studies, which also exclude the confounding effect of phacoemulsification, will determine how effective these newer devices are, and whether they can be inserted sufficiently atraumatically, without pre-dilating the canal, to prevent fibrosis. it is hoped that this new interest in schlemm’s canal surgery, now rekindled, will continue to grow. References: 1 Stegmann R, Pienaar A, Miller D. Viscocanalostomy for open-angle glaucoma in black African patients: J Cataract Refract Surg 1991; 25: 316-322. 2 Brüggemann A, Müller M. Trabeculectomy versus Canaloplasty - Utility and Cost- Effectiveness Analysis: Klin Monbl Augenheilkd 2012:229(11):1118-23. 3 Salgado J, Sauer J, Körber N, Grehn F, Klink T. Quality of Life in glaucoma surgery: canaloplasty versus trabeculectomy: European Glaucoma Society Congress, Copenhagen June 2012. 4 Shuman A, Polansky J, Merkel C, Alvarado J. Tissue Plasminogen Activator in Cultured Human Trabecular Meshwork Cells: Invest Oph & Vis Sci 1988: 29(3):401-5. 5 Grieshaber M, Pienaar A, Oliver J, Stegmann R. Canaloplasty for primary open angle glaucoma: long-term outcome: Br J Ophthal 2010:94(11):1478-82. 6 Bull H, von Wolff K, Körber N, Tetz M. Three-year canaloplasty outcomes for the treatment of open-angle glaucoma: European study results: Graefes Arch Clin Exp Ophthalmol 2011:249:1537-45. Emanuel Rosen Chairman ESCRS Publications Committee Noel Alpins AUSTRALIA Bekir Aslan TURKEY Bill Aylward UK Peter Barry IRELAND Roberto Bellucci ITALY Hiroko Bissen-Miyajima JAPAN John Chang CHINA Alaa El DanasourySAUDI ARABIA Oliver Findl AUSTRIA I Howard Fine USA Jack Holladay USA Vikentia Katsanevaki GREECE Thomas Kohnen GERMANY Anastasios Konstas GREECE Dennis Lam HONG KONG Boris Malyugin RUSSIA Marguerite McDonald USA Cyres Mehta INDIA Thomas Neuhann GERMANY Rudy Nuijts THE NETHERLANDS Gisbert Richard GERMANY Robert Stegmann SOUTH AFRICA Ulf Stenevi SWEDEN Emrullah Tasindi TURKEY Marie-Jose Tassignon BELGIUM Manfred Tetz GERMANY Carlo Enrico Traverso ITALY Roberto Zaldivar ARGENTINA Oliver Zeitz GERMANY Clive Peckar FRCOphth is a medical editor for EuroTimes EUROTIMES | Volume 18 | Issue 7/8